Program
beruzatatug pelitecan
Also written as “YL202”, “BNT326” and “YL202 should be intravenously infused”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Melanoma, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| MediLink Therapeutics (Suzhou) | 77 open or running | phase 3since Feb 10, 2026 | Dec 1, 2022 | Nov 2026phase 2 · NCT06107686 |
| BioNTech | 22 open or running | phase 2since Jul 3, 2025 | Jul 3, 2025 | Mar 2028phase 2 · NCT07070232 |
Also a collaborator on its studies: BioNTech (Shanghai) Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 1, 2022First study: phase 1 study in Carcinoma, Non-Small-Cell LungNew to MediLink Therapeutics (Suzhou)MediLink Therapeutics (Suzhou) · NCT05653752 · 80 enrolled · United States, China
- Oct 20, 2023Phase 2 study in Breast NeoplasmsMediLink Therapeutics (Suzhou) · NCT06107686 · 200 planned · China
- May 16, 2024Phase 2 study in Breast NeoplasmsMediLink Therapeutics (Suzhou) · NCT06439771 · 180 planned · China
- Jul 3, 2025BioNTech’s first study: phase 2 study in Lethal Congenital Contracture Syndrome 2New to BioNTechBioNTech · NCT07070232 · 1,438 planned · United States, Australia, Belgium and more
- Aug 1, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungBioNTech · NCT07111520 · 880 planned · United States, Australia, China and more
- Sep 3, 20252 phase 2 studiesMediLink Therapeutics (Suzhou) · NCT07169994, NCT07202364
- Feb 10, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungPhase 3 reachedMediLink Therapeutics (Suzhou) · NCT07416994 · 440 planned · China
- Mar 4, 2026Phase 3 study in Breast NeoplasmsMediLink Therapeutics (Suzhou) · NCT07461454 · 376 planned · China
- Oct 14, 2026Primary completion moved from 2026-07-30 to 2027-07-30Date moved laterphase 2 · +12 months · NCT06439771
- Oct 14, 2026Primary completion moved from 2026-08-31 to 2027-01-31Date moved laterphase 2 · +5 months · NCT07202364
Ahead
- Nov 2026Primary completion: phase 2 study in Breast NeoplasmsMediLink Therapeutics (Suzhou) · NCT06107686
- Dec 2026Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungMediLink Therapeutics (Suzhou) · NCT05653752
- Jan 31, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungMediLink Therapeutics (Suzhou) · NCT07202364
- Jul 30, 2027Primary completion: phase 2 study in Breast NeoplasmsMediLink Therapeutics (Suzhou) · NCT06439771
TargetBeta
“An antibody-drug conjugate (ADC) composed of beruzatatug, an immunoglobulin G1 (IgG1) monoclonal antibody directed against human epidermal growth factor receptor 3 (HER3; ErbB3) ”NCIt, by rule
Other programs on ERBB3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| patritumab deruxtecan | Merck | phase 3 | 17 |
| ruzaltatug rezetecan | Jiangsu HengRui Medicine | phase 3 | 8 |
| JSKN016rule | Alphamab Oncology | phase 3 | 5 |
| SYS6023rule | CSPC Pharmaceutical Group | phase 2 | 2 |
| Anti-HER3/Anti-MUC1 Bispecific Antibody-drug Conjugate DM002rule | xadcera-biopharmaceutical-suzhou-co-ltd | phase 2 | 1 |
| Anti-HER3/Exatecan Antibody-drug Conjugate ENV-501rule | hummingbird-bioscience | phase 2 | 1 |
| Anti-EGFR/Anti-HER3 Bispecific Antibody-drug Conjugate AVZO-1418rule | avenzo-therapeutics-inc | phase 2 | 1 |
| KHN922rule | Chengdu Kanghong Pharmaceutical Group | phase 2 | 1 |
| CS5007rule | CStone Pharmaceuticals | phase 1 | 1 |
| JSKN016HCrule | Alphamab Oncology | phase 1 | 1 |
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07461454Breast Neoplasms · China | 3 | Recruiting | MediLink Therapeutics (Suzhou) | Dec 31, 2027 | 376 |
| NCT07416994Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | MediLink Therapeutics (Suzhou) | Aug 31, 2028 | 440 |
| NCT07202364Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | MediLink Therapeutics (Suzhou) | Jan 31, 2027 | 100 |
| NCT07169994Breast Neoplasms · China | 2 | Recruiting | MediLink Therapeutics (Suzhou) | Sep 1, 2026 | 414 |
| NCT07111520Carcinoma, Non-Small-Cell Lung · United States, Australia, China and more | 2 | Recruiting | BioNTech | Nov 2028 | 880 |
| NCT07070232Lethal Congenital Contracture Syndrome 2 · United States, Australia, Belgium and more | 2 | Recruiting | BioNTech | Mar 2028 | 1,438 |
| NCT06439771Breast Neoplasms · China | 2 | Recruiting | MediLink Therapeutics (Suzhou) | Jul 30, 2027 | 180 |
| NCT06107686Breast Neoplasms · China | 2 | Recruiting | MediLink Therapeutics (Suzhou) | Nov 2026 | 200 |
| NCT05653752Carcinoma, Non-Small-Cell Lung · United States, China | 1 | Active, not recruiting | MediLink Therapeutics (Suzhou) | Dec 2026 | 80 |
How it is read
Names in the registry
- “YL202”, 4 entries
- “BNT326”, 2 entries
- “YL202 should be intravenously infused”, 2 entries
- “YL202 for injection; Toripalimab injection”, 1 entry
- “YL202 for injection; Furmonertinib Mesilate Tablets”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Breast Neoplasms, 4 studies
- Melanoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.